Abstract
Patent ductus arteriosus is a common problem in very low birth weight infants. Prostaglandin synthesis inhibitors such as indomethacin and ibuprofen are widely used preferred medications for ductal closure but the question of which one should be preferred is controversial. There are some studies in the literature comparing their pharmacokinetics, efficacy, side effects and long-term outcomes. In this review we aimed to focus on prostaglandin synthesis inhibitors with their pharmacodynamic and pharmacokinetic in relation to oral and intravenous forms. Oral ibuprofen seems to be an effective and cheap alternative to the intravenous forms. Studies in extremely low birth weight infants that also evaluate the neurodevelopment will clarify its use.
Keywords: Ibuprofen, indomethacin, patent ductus arteriosus, pharmacodynamics, pharmacokinetics, prostaglandin synthesis inhibitors, TREATMENT, Cochrane metaanalysis, development, PDA closure.
Current Clinical Pharmacology
Title:Pharmacological Management of PDA: Oral Versus Intravenous Medications
Volume: 7 Issue: 4
Author(s): Gamze Demirel, Omer Erdeve and Ugur Dilmen
Affiliation:
Keywords: Ibuprofen, indomethacin, patent ductus arteriosus, pharmacodynamics, pharmacokinetics, prostaglandin synthesis inhibitors, TREATMENT, Cochrane metaanalysis, development, PDA closure.
Abstract: Patent ductus arteriosus is a common problem in very low birth weight infants. Prostaglandin synthesis inhibitors such as indomethacin and ibuprofen are widely used preferred medications for ductal closure but the question of which one should be preferred is controversial. There are some studies in the literature comparing their pharmacokinetics, efficacy, side effects and long-term outcomes. In this review we aimed to focus on prostaglandin synthesis inhibitors with their pharmacodynamic and pharmacokinetic in relation to oral and intravenous forms. Oral ibuprofen seems to be an effective and cheap alternative to the intravenous forms. Studies in extremely low birth weight infants that also evaluate the neurodevelopment will clarify its use.
Export Options
About this article
Cite this article as:
Demirel Gamze, Erdeve Omer and Dilmen Ugur, Pharmacological Management of PDA: Oral Versus Intravenous Medications, Current Clinical Pharmacology 2012; 7 (4) . https://dx.doi.org/10.2174/157488412803305830
DOI https://dx.doi.org/10.2174/157488412803305830 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
The Mechanisms of Actions of Aldosterone and its Antagonists in Cardiovascular Disease
Current Pharmaceutical Design Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology Detection of Obstructive Sleep Apnea Using Internet of Things: A Review
International Journal of Sensors, Wireless Communications and Control The Role of Statins in Preventing the Progression of Congestive Heart Failure in Patients with Metabolic Syndrome
Current Pharmaceutical Design Leptin in Non-Autoimmune Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Computational Models and Methods for Drug Target Prediction and Drug Repositioning
Combinatorial Chemistry & High Throughput Screening Massively Parallel Screening of the Receptorome
Combinatorial Chemistry & High Throughput Screening Pitavastatin and 4-Hydroxy-3-Methoxyacetophenone (HMAP) Reduce Cognitive Dysfunction in Vascular Dementia During Experimental Diabetes
Current Neurovascular Research Synthesis and Endothelin Receptors Binding Affinity of New 1,3,5- Substituted Pyrrole-2-Carboxylic Acid Derivatives
Medicinal Chemistry A Brief Review of Blue- and Bilberries’ Potential to Curb Cardio-Metabolic Perturbations: Focus on Diabetes
Current Pharmaceutical Design Goto-kakizaki Rats: Its Suitability as Non-obese Diabetic Animal Model for Spontaneous Type 2 Diabetes Mellitus
Current Diabetes Reviews Global Life-Long Health Benefits of Repression of Hypothalamic NPY System by Central Leptin Gene Therapy
Current Topics in Medicinal Chemistry Discovery and Optimization of 1-(4-chloro-3-(trifluoromethyl)- phenyl)-3-(2-(amino)pyridin-3-yl)ureas as Novel KDR Kinase Inhibitors
Medicinal Chemistry The Emerging Role of Complement C3 as A Biomarker of Insulin Resistance and Cardiometabolic Diseases: Preclinical and Clinical Evidence
Reviews on Recent Clinical Trials A New Role for Zn(II) Aminopeptidases: Antigenic Peptide Generation and Destruction
Current Pharmaceutical Design Small-Molecules Targeting Kinases Involved in Pulmonary Hypertension: a Patent Review (2010-2015)
Current Medicinal Chemistry Mapping of the Active Site of Proteases in the 1960s and Rational Design of Inhibitors/Drugs in the 1990s
Current Protein & Peptide Science Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Current Diabetes Reviews In Vitro Inhibition of Key Enzymes Related to Diabetes by the Aqueous Extracts of Some Fruits of West Bengal, India
Current Nutrition & Food Science Study of Prolactin Permeation Through the Pericardium and Its Bioavailability
Protein & Peptide Letters